[go: up one dir, main page]

NO994394L - Activated vitamin K-dependent blood factor and method for producing it - Google Patents

Activated vitamin K-dependent blood factor and method for producing it

Info

Publication number
NO994394L
NO994394L NO994394A NO994394A NO994394L NO 994394 L NO994394 L NO 994394L NO 994394 A NO994394 A NO 994394A NO 994394 A NO994394 A NO 994394A NO 994394 L NO994394 L NO 994394L
Authority
NO
Norway
Prior art keywords
blood factor
producing
dependent blood
activated vitamin
vitamin
Prior art date
Application number
NO994394A
Other languages
Norwegian (no)
Other versions
NO994394D0 (en
Inventor
Peter Turecek
Guenter Richter
Anton Philapitsch
Hans-Peter Schwarz
Johann Eibl
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Publication of NO994394D0 publication Critical patent/NO994394D0/en
Publication of NO994394L publication Critical patent/NO994394L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Oppfinnelsen omfatter en fremgangsmåte for aktivering av en vitamin K-avhengig blodfaktor ved behandling med en protease avledet fra planter eller prokaryoter. Oppfinnelsen omfatter også blodfaktoren fremstilt ifølge oppfinnelsen, som ikke viser noen dyreproteaseforurensing, i tillegg til et farmasøytisk preparat og et sett for medisinsk anvendelse.The invention comprises a method for activating a vitamin K-dependent blood factor by treatment with a plant or prokaryote protease. The invention also encompasses the blood factor of the invention which shows no animal protease contamination, in addition to a pharmaceutical composition and a kit for medical use.

NO994394A 1997-03-12 1999-09-10 Activated vitamin K-dependent blood factor and method for producing it NO994394L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19710190A DE19710190A1 (en) 1997-03-12 1997-03-12 Activated vitamin K-dependent blood factor and method for its production
PCT/EP1998/001364 WO1998040474A2 (en) 1997-03-12 1998-03-10 Activated vitamin k-dependent blood factor and method for the production thereof

Publications (2)

Publication Number Publication Date
NO994394D0 NO994394D0 (en) 1999-09-10
NO994394L true NO994394L (en) 1999-11-11

Family

ID=7823110

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994394A NO994394L (en) 1997-03-12 1999-09-10 Activated vitamin K-dependent blood factor and method for producing it

Country Status (9)

Country Link
EP (1) EP0968280A1 (en)
JP (1) JP2001514516A (en)
AU (1) AU740727B2 (en)
CA (1) CA2284122A1 (en)
DE (1) DE19710190A1 (en)
HU (1) HUP0001505A3 (en)
NO (1) NO994394L (en)
SK (1) SK124699A3 (en)
WO (1) WO1998040474A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI684599B (en) * 2014-08-12 2020-02-11 美商巴克斯歐塔公司 Factor X activation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3171072D1 (en) * 1981-06-25 1985-07-25 Stroetmann M Serapharm Enriched plasma derivative for promoting wound sealing and wound covering
EP0485504B1 (en) * 1989-08-11 1993-12-01 Zymogenetics, Inc. Cell culture methods for producing activated protein c
DE69130990T2 (en) * 1990-02-20 1999-12-02 Baxter International Inc., Deerfield Purified, virus-free human thrombin
WO1993006855A1 (en) * 1991-10-11 1993-04-15 Novo Nordisk A/S Hemostatic composition for local hemostasis
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
JP3404038B2 (en) * 1991-12-31 2003-05-06 ザイモジェネティクス，インコーポレイティド Method for producing thrombin
AT397390B (en) * 1992-04-06 1994-03-25 Immuno Ag PROCESS FOR CLEAVING PROTEINS
US5514373A (en) * 1992-05-22 1996-05-07 Harris, Jr.; Roosevelt D. Topical preparation
JPH08509965A (en) * 1993-03-15 1996-10-22 ファーマ・パシフィック・ピーティーワイ・リミテッド Therapeutic agent and method
DE4325872C1 (en) * 1993-08-02 1994-08-04 Immuno Ag Virus inactivated factor Xa preparation
DE4430205A1 (en) * 1994-08-26 1996-02-29 Behringwerke Ag Compositions suitable as antidotes for blood anticoagulants and their use
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
DE19503338C2 (en) * 1995-02-02 1998-07-30 Lohmann Therapie Syst Lts Pharmaceutical form for delivering collagenase to wounds and process for their production and their use

Also Published As

Publication number Publication date
HUP0001505A3 (en) 2002-01-28
WO1998040474A2 (en) 1998-09-17
SK124699A3 (en) 2000-06-12
NO994394D0 (en) 1999-09-10
JP2001514516A (en) 2001-09-11
EP0968280A1 (en) 2000-01-05
AU740727B2 (en) 2001-11-15
CA2284122A1 (en) 1998-09-17
DE19710190A1 (en) 1998-09-17
HUP0001505A1 (en) 2000-09-28
WO1998040474A3 (en) 1999-02-11
AU6829598A (en) 1998-09-29

Similar Documents

Publication Publication Date Title
NO20055832L (en) Preparation and use of arylalkyl acid derivatives for the treatment of obesity
NO20045521L (en) Diarylurea derivatives useful for the treatment of protein kinase-dependent diseases
NO20050795L (en) Compounds, compositions and methods for utilizing the same
NO20055863L (en) W-carboxyaryl-substituted diphenylurea compounds as raf kinase inhibitors
DK1501496T3 (en) Formulations containing amiodarone and sulfalkyl ether cyclodextrin
DE60115842D1 (en) VALVE ARRANGEMENT
NO20053855L (en) 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases.
NO20064347L (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
UY27940A1 (en) FORMULATION OF HUMAN ANTIBODIES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH TNF-A
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
GB0222514D0 (en) Organic compounds
NO20045354L (en) Methods for the treatment of angiogenesis, tumor growth and metastasis
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
NO20072290L (en) Organic compounds.
DE60233433D1 (en) PHARMACEUTICAL PREPARATION containing a catechin, ascorbic acid, proline and lysine FOR THE TREATMENT OF NEOPLASTIC DISEASES
ATE372776T1 (en) MEDICINAL PRODUCTS CONTAINING DEUTERIUM FOR THE TREATMENT OF SUBJECT DISEASE
NO331082B1 (en) Formulation of kahalalide F, comprising such a formulation, as well as reconstituted solution thereof and use of a diluted reconstituted solution for the manufacture of a medicament for the treatment of cancer
DK1397681T3 (en) Method of identifying agents for the treatment of diabetes
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
NO20044530L (en) Procedure for the treatment of cognitive disorders
NO20062605L (en) Pharmaceutical formulation containing flavoring substances with improved pharmaceutical properties
EA200601288A1 (en) 1,3-DIPHENYLPROP-2-EN-1-SHE DERIVATIVES, METHOD OF THEIR RECEIVING AND APPLICATION
DK1237562T3 (en) Process for the preparation of micania extracts containing micanolide and dihydromycanolide and use in the treatment of proliferative diseases
NO20061236L (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hoziiton

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application